Events & Implementation Activities
Where personalised medicine moves from discussion to delivery.
IPM Alliance convenes political, scientific, clinical, patient, industry and health-system stakeholders to address the practical barriers that prevent personalised medicine from reaching patients.
Across political sessions, implementation labs, congress-side meetings, expert roundtables and business-facing innovation meetings, our events are designed to produce more than discussion. They create policy signals, implementation briefs, pathway prototypes, stakeholder takeaways, readiness maps and follow-up workstreams.
Events
Featured upcoming activities
Explore upcoming IPM Alliance events and implementation activities across global policy, regional engagement, scientific congresses and business-facing innovation settings.
China Precision Oncology Sessions
A China-focused precision oncology implementation event examining how clinical trials and AI-enabled innovation can translate into trusted, timely and equitable patient access. The event will connect global evidence generation, local implementation, trial matching, diagnostics, patient navigation, real-world evidence and responsible AI governance.
Expected output:
The event is designed to produce China-focused implementation outputs, including: - practical principles for aligning clinical trial design with local access needs; - recommendations for integrating biomarker testing, imaging, digital pathology and trial matching into routine care; - approaches for using real-world evidence to support regulatory, HTA and reimbursement decisions; - a patient-centred framework for responsible AI leapfrogging in precision oncology; - priority AI use cases for near-term access improvement; - China-focused collaboration opportunities around hospital research networks, registries, digital pathology validation, trial matching, trusted data governance and real-world evidence.
ECP 2026 Pathology Policy Session
A side meeting alongside ECP 2026 on the system conditions that turn pathology innovation into routine patient benefit. It examines trustworthy AI, liquid biopsy and advanced molecular diagnostics, from validation and laboratory readiness to reimbursement, clinical reporting and timely action.
Expected output:
Stockholm Pathology Readiness Brief: a concise post-meeting synthesis setting out the conditions needed for trustworthy AI-enabled pathology, liquid biopsy and advanced molecular diagnostics to deliver timely, equitable and quality-assured precision oncology access. The brief will integrate: - A European roadmap for trustworthy AI-enabled pathology, including validation, quality assurance, human oversight, reimbursement and equity safeguards. - An advanced diagnostics implementation framework covering clinical utility, integrated testing pathways, laboratory readiness, molecular tumour boards, reimbursement and patient access.
ASCO Oncology Pillar Launch
A high-level ASCO-side launch session introducing the Oncology Pillar of the International Alliance for Personalised Medicine. The session will bring together oncology leaders, clinical innovators, policymakers, payers, HTA and regulatory experts, diagnostics and data partners, patient voices and industry leaders to discuss how precision oncology can move from breakthrough science to routine, equitable real-world delivery.
Expected output:
Oncology Pillar launch, Leadership Circle, founding stakeholder alignment and 12-month roadmap.
From Capital to Care
A J.P. Morgan Week side event focused on how personalised medicine can move from scientific promise and investment potential to routine patient benefit. The forum will examine the policy, investment, regulatory, reimbursement, data, AI and health-system conditions needed to make personalised medicine investable, scalable, reimbursable and accessible.
Expected output:
The event is designed to produce a Policy-Investor Compact for Personalised Medicine, setting out practical commitments across: - trusted data infrastructure for personalised medicine; - credible evaluation standards for AI and digital health tools; - earlier molecular profiling and matched therapies; - alignment of regulatory, HTA and reimbursement pathways; - investment in diagnostic readiness and workforce capacity; - business models that balance innovation, sustainability and patient access; - measurable patient benefit as the core test of value.
Irish Presidency Policy Conference
A Dublin policy conference during the Irish Presidency focused on how Europe can move personalised medicine from innovation to routine patient benefit. The event will examine the practical barriers between scientific progress and access, including innovation funding, reimbursement, diagnostic readiness, clinical trials, data infrastructure and health-system implementation.
Expected output:
A Dublin Personalised Medicine Access Brief setting out practical policy priorities from the conference, including: - how Europe can strengthen the innovation-to-access pathway; - whether a European Health Innovation Fund or similar mechanism could support earlier and fairer adoption; what diagnostic infrastructure is needed for precision oncology; - how clinical trial evidence, regulation, HTA, reimbursement and diagnostic readiness can be better aligned; - what follow-up commitments should be taken forward after the Irish Presidency conference.
New York Precision Oncology Readiness Accord
A high-level political session during UNGA 2026 focused on launching the New York Precision Oncology Readiness Accord. The session will frame precision oncology readiness as an access and implementation priority, bring together political, diplomatic, clinical, patient and stakeholder voices, and launch a 90-day validation process toward a 12-month implementation roadmap.
Expected output:
The session is designed to deliver: - signature of the New York Precision Oncology Readiness Accord; - launch of a 90-day validation process; basis for a 12-month implementation roadmap; - shared readiness commitments across diagnostics, trials, evidence generation, reimbursement, regional access and patient pathways; - political and stakeholder alignment around precision oncology as an access and implementation priority.
ESMO 2026 Personalised Oncology Session
A full-day ESMO-side session in Madrid focused on how personalised oncology can move from molecular insight to measurable patient access. The meeting will examine whether health systems can identify the right patient, deliver the right test, interpret the result, act on eligibility and measure whether access has improved.
Expected output:
The session is designed to produce practical post-ESMO outputs, including: - ESMO Personalised Oncology Access Statement; - five to seven implementation priorities across diagnostics, treatment access, reimbursement, data, prevention, supportive care and equity; - eligibility-to-access pathway map; - post-ESMO policy communiqué; - stakeholder consultation route involving clinicians, patients, policymakers, payers, diagnostics leaders, researchers and innovation partners; - follow-up route with SYNTHIA, BRECISE, SPARC, ON-COME and iBeChange.